Terns Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

TERN

Rang in aandelen #3572
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Aandeelprijs
$52.95
Laatst gesynchroniseerd: 2026-05-15
Marktkapitalisatie
$4.77B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
514.27%
Land
US
Handel Terns Pharmaceuticals, Inc. (TERN)

Categorie

Healthcare
Aandelsplitsingen voor Terns Pharmaceuticals, Inc. (TERN)
Het aandeel Terns Pharmaceuticals, Inc. (symbool: TERN) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel TERN dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen TERN.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL